10-Q · May 13, 2026
DarioHealth released its Q1 2026 results reflecting a revenue decline of 17.3% year-over-year, amounting to $5,584k compared to $6,752k in Q1 2025. The company continues to face challenges with net losses of $8,249k,…
Earnings analysis · 10-Q
DRIO earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
The supplied extract does not include the consolidated income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial discussion, so current-quarter revenue, margins, EPS, cash flow, and…
Read full summary
The supplied extract does not include the consolidated income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial discussion, so current-quarter revenue, margins, EPS, cash flow, and balance-sheet trends cannot be assessed. Item 1A states that there were no material changes from the risk factors in the 2025 Form 10-K. The filing references the financial statements in Exhibit 101.1 and financing-related exhibits 4.1, 10.1, and 10.2, but provides no quantitative operating outlook in the supplied text.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What to watch
-
Risk factors unchanged
The company states in Item 1A that there have been no material changes to the risk factors disclosed in its Annual Report on Form 10-K for the year ended December 31, 2025. Existing risks therefore remain applicable, but the supplied filing text does not identify any newly added or expanded risk.
Management's outlook
No quantitative revenue or EPS outlook is included in the supplied 10-Q text; numeric outlook may be deferred to the earnings release or call.
Earlier filings 4
10-K · March 19, 2026
DarioHealth positions itself as a vertically integrated whole‑person digital health platform combining FDA‑cleared hardware, AI trained on proprietary device data, and behavioral coaching, with B2B (employers, health…
10-Q · May 14, 2025
DarioHealth reported Q1 revenue of $6,752,000, up from $5,758,000 in Q1 2024, with gross profit of $3,882,000 (57.5% margin). Operating loss narrowed to $9,409,000 from $17,855,000 a year ago, but net loss remained…
10-K · March 10, 2025
DarioHealth positions itself as a whole-person digital health platform built from D2C roots and multiple acquisitions (~$525 million invested in acquired companies) with over 5 million users and more than 90 clinical…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.